BMY Bristol Myers Squibb Co

By Colin Kellaher

Bristol Myers Squibb Co. on Tuesday said the European Commission approved the expanded use of its multiple-sclerosis drug Zeposia for the treatment of adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease.

The New York biopharmaceutical company said the approval covers patients who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Bristol Myers last year received U.S. and European approval for Zeposia in adults with relapsing forms of multiple sclerosis and earlier this year received U.S. Food and Drug Administration approval for the drug ulcerative colitis. The company is also evaluating the drug as a treatment for Crohn's disease.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

November 23, 2021 07:29 ET (12:29 GMT)

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024

Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024